



ALTERNATIVE TO PTO/SB/08A/B (09/06)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/808,880
				Filing Date	March 24, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	1	of	1	Attorney Docket Number	475512000400

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
8	1.	Edvardsson, U. et al. (2003). "Hepatic Protein Expression of Lean Mice and Obese Diabetic Mice Treated with Peroxisome Proliferator-activated Receptor Activators," <i>Proteomics</i> 3:468-478.	
8	2.	Ferrand, C. et al. (2006). "Prolonged Treatment with the β_3 -adrenergic Agonist CL 316243 Induces Adipose Tissue Remodeling in Rat but not in Guinea Pig: 1) Fat Store Depletion and Desensitization of β -adrenergic Responses," <i>J. Physiol. Biochem.</i> 62(2):89-99.	
8	3.	McTernan, P.G. et al. (May 2002). "Insulin and Rosiglitazone Regulation of Lipolysis and Lipogenesis in Human Adipose Tissue in Vitro," <i>Diabetes</i> 51:1493-1498.	
8	4.	Nichols, G.A. et al. (2007). "Weight Changes Following the Initiation of New Anti-hyperglycaemic Therapies," <i>Diabetes, Obesity and Metabolism</i> 9:96-102.	
8	5.	Patel, N.G. et al. (January 2003). "Differential Regulation of Lipogenesis and Leptin Production by Independent Signaling Pathways and Rosiglitazone During Human Adipocyte Differentiation," <i>Diabetes</i> 52:43-50.	
8	6.	Phinney, S.D. et al. (October 1995). "Evidence for Increasing Lipogenesis with BMI and Following Eucaloric High Carbohydrate Feeding in Women," <i>Obesity Research</i> , NAASO-SSIB Annual Meeting, Baton Rouge, LA, 3(Suppl. 3): Abstract O83.	
8	7.	Siguel, E. (June 30, 1998). "Diagnosing Essential Fatty Acid Deficiency," <i>Circulation</i> 97(25):2580-2583.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	9/10/07
-----------------------	--	--------------------	---------

pa- 1140637